Our Reports
Automotive ReportsElectronics & SemiconductorTelecom & ITTechnology & ITConsumer GoodsHealthcareFood & BeveragesChemical
Our Links
About UsContact UsPress ReleaseNewsOur Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

North America Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

Published Date : 30-Jun-2022

Pages: 112

Formats: PDF

The North America Peptide Therapeutics Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).

Peptides can also benefit the skin of a person. The skin barrier source can be identified as the line of defense of a body that protects the skin from UV rays, pollution, bacteria, and other toxins. Excessive exfoliation, contact with cigarette smoke as well as other pollution particles, and even lack of sleep can all harm the skin barrier. Peptides help in the formation of a robust barrier. Collagen can help to fill up the skin and lips. Fine lines and wrinkles will be less evident when the skin is firmer and plumper. Peptides are also found in elastin fibers, which are another form of protein.

When it comes to peptide stability and half-life, another technique to consider is lipidation. Because the lipid chain non-covalently interacts with serum albumin to raise the molecular weight, attaching a lipid chain to the peptide head group inhibits proteolytic attack and thereby reduces renal filtration. Because of its affinity for human serum albumin, studies on detemir, a lipidated analog of insulin, indicated that it had a longer action. Furthermore, lipidation has been demonstrated to improve peptide interaction with cell membranes, enabling them to be absorbed into the cell more readily than peptides lacking the lipid component.

The adoption of novel drugs for the treatment of various diseases is increasing in this region. According to the National Library of Medicines, the Food and Drug Administration (FDA) approved 53 medications in 2020, bringing the total number of approved entities (new chemical biologics and entities) to 228 in the last five years (2016–2020). Six peptides and oligonucleotides are among the 53 medications that were approved in 2020. In this context, 23 TIDES have been authorized in the last five years. These figures bolster the TIDES market, which contributes to approximately 10% of the overall in terms of number of medications.

Moreover, peptides and proteins have appeared with a slew of new uses in the diagnostic and therapeutic sectors as a result of major advances in biologics and biopharmaceuticals over the past few years. According to current estimates of the organization, the market for peptide and protein therapeutics accounts for around 10% of the total pharmaceutical market and is expected to grow even more in the future. Since the early 1980s, the US Food and Drug Administration has approved 239 therapeutic proteins and peptides for clinical use. With the increasing adoption of peptides along with the upcoming developments in the sector, the growth of the peptide therapeutics market is increasing.

The US market dominated the North America Peptide Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,967.9 million by 2028. The Canada market is anticipated to grow at a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 6.6% during (2022 - 2028).

Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Peptide Therapeutics Market is Estimated to reach $58.4 Billion by 2028, at a CAGR of 6.3%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

  • Innovative
  • Generic

By Route of Administration

  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others

By Synthesis Technology

  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology

By Type of Manufacturers

  • In-house
  • Outsourced

By Application

  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.1 Objectives
1.2 Market Scope
1.3 Segmentation
1.3.1 North America Peptide Therapeutics Market, by Type
1.3.2 North America Peptide Therapeutics Market, by Route of Administration
1.3.3 North America Peptide Therapeutics Market, by Synthesis Technology
1.3.4 North America Peptide Therapeutics Market, by Type of Manufacturers
1.3.5 North America Peptide Therapeutics Market, by Application
1.3.6 North America Peptide Therapeutics Market, by Country
1.4 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)

Chapter 4. North America Peptide Therapeutics Market by Type
4.1 North America Innovative Market by Country
4.2 North America Generic Market by Country

Chapter 5. North America Peptide Therapeutics Market by Route of Administration
5.1 North America Parenteral Route Market by Country
5.2 North America Pulmonary Market by Country
5.3 North America Mucosal Market by Country
5.4 North America Oral Route Market by Country
5.5 North America Others Market by Country

Chapter 6. North America Peptide Therapeutics Market by Synthesis Technology
6.1 North America Liquid Phase Peptide Synthesis (LPPS) Market by Country
6.2 North America Solid Phase Peptide Synthesis (SPPS) Market by Country
6.3 North America Hybrid Technology Market by Country

Chapter 7. North America Peptide Therapeutics Market by Type of Manufacturers
7.1 North America In-house Market by Country
7.2 North America Outsourced Market by Country

Chapter 8. North America Peptide Therapeutics Market by Application
8.1 North America Metabolic Market by Country
8.2 North America Cardiovascular Disorder Market by Country
8.3 North America GIT & Renal Market by Country
8.4 North America Antiinfection & Dermatology Market by Country
8.5 North America Respiratory Market by Country
8.6 North America Central Nervous System Market by Country
8.7 North America Cancer Market by Country
8.8 North America Pain Market by Country
8.9 North America Others Market by Country

Chapter 9. North America Peptide Therapeutics Market by Country
9.1 US Peptide Therapeutics Market
9.1.1 US Peptide Therapeutics Market by Type
9.1.2 US Peptide Therapeutics Market by Route of Administration
9.1.3 US Peptide Therapeutics Market by Synthesis Technology
9.1.4 US Peptide Therapeutics Market by Type of Manufacturers
9.1.5 US Peptide Therapeutics Market by Application
9.2 Canada Peptide Therapeutics Market
9.2.1 Canada Peptide Therapeutics Market by Type
9.2.2 Canada Peptide Therapeutics Market by Route of Administration
9.2.3 Canada Peptide Therapeutics Market by Synthesis Technology
9.2.4 Canada Peptide Therapeutics Market by Type of Manufacturers
9.2.5 Canada Peptide Therapeutics Market by Application
9.3 Mexico Peptide Therapeutics Market
9.3.1 Mexico Peptide Therapeutics Market by Type
9.3.2 Mexico Peptide Therapeutics Market by Route of Administration
9.3.3 Mexico Peptide Therapeutics Market by Synthesis Technology
9.3.4 Mexico Peptide Therapeutics Market by Type of Manufacturers
9.3.5 Mexico Peptide Therapeutics Market by Application
9.4 Rest of North America Peptide Therapeutics Market
9.4.1 Rest of North America Peptide Therapeutics Market by Type
9.4.2 Rest of North America Peptide Therapeutics Market by Route of Administration
9.4.3 Rest of North America Peptide Therapeutics Market by Synthesis Technology
9.4.4 Rest of North America Peptide Therapeutics Market by Type of Manufacturers
9.4.5 Rest of North America Peptide Therapeutics Market by Application

Chapter 10. Company Profiles
10.1 Eli Lilly And Company
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.5.2 Acquisition and Mergers:
10.1.5.3 Approvals and Trails:
10.2 AstraZeneca PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expenses
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisition and Mergers:
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expenses
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals and Acquisitions:
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisition and Mergers:
10.4.5.2 Approvals and Trails:
10.5 Pfizer, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional & Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Acquisition and Mergers:
10.6 Sanofi S.A.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 GlaxoSmithKline PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expense
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals and Trails:
10.9 Lonza Group AG
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Segmental and Regional Analysis
10.9.4 Research & Development Expenses
10.10. Amgen, Inc.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Partnerships, Collaborations, and Agreements:
TABLE 1 North America Peptide Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 North America Peptide Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Peptide Therapeutics Market
TABLE 4 Acquisition and Mergers– Peptide Therapeutics Market
TABLE 5 Approvals and trails– Peptide Therapeutics Market
TABLE 6 North America Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 7 North America Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 8 North America Innovative Market by Country, 2018 - 2021, USD Million
TABLE 9 North America Innovative Market by Country, 2022 - 2028, USD Million
TABLE 10 North America Generic Market by Country, 2018 - 2021, USD Million
TABLE 11 North America Generic Market by Country, 2022 - 2028, USD Million
TABLE 12 North America Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
TABLE 13 North America Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
TABLE 14 North America Parenteral Route Market by Country, 2018 - 2021, USD Million
TABLE 15 North America Parenteral Route Market by Country, 2022 - 2028, USD Million
TABLE 16 North America Pulmonary Market by Country, 2018 - 2021, USD Million
TABLE 17 North America Pulmonary Market by Country, 2022 - 2028, USD Million
TABLE 18 North America Mucosal Market by Country, 2018 - 2021, USD Million
TABLE 19 North America Mucosal Market by Country, 2022 - 2028, USD Million
TABLE 20 North America Oral Route Market by Country, 2018 - 2021, USD Million
TABLE 21 North America Oral Route Market by Country, 2022 - 2028, USD Million
TABLE 22 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 23 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 24 North America Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
TABLE 25 North America Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
TABLE 26 North America Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2018 - 2021, USD Million
TABLE 27 North America Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2022 - 2028, USD Million
TABLE 28 North America Solid Phase Peptide Synthesis (SPPS) Market by Country, 2018 - 2021, USD Million
TABLE 29 North America Solid Phase Peptide Synthesis (SPPS) Market by Country, 2022 - 2028, USD Million
TABLE 30 North America Hybrid Technology Market by Country, 2018 - 2021, USD Million
TABLE 31 North America Hybrid Technology Market by Country, 2022 - 2028, USD Million
TABLE 32 North America Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
TABLE 33 North America Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
TABLE 34 North America In-house Market by Country, 2018 - 2021, USD Million
TABLE 35 North America In-house Market by Country, 2022 - 2028, USD Million
TABLE 36 North America Outsourced Market by Country, 2018 - 2021, USD Million
TABLE 37 North America Outsourced Market by Country, 2022 - 2028, USD Million
TABLE 38 North America Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
TABLE 39 North America Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
TABLE 40 North America Metabolic Market by Country, 2018 - 2021, USD Million
TABLE 41 North America Metabolic Market by Country, 2022 - 2028, USD Million
TABLE 42 North America Cardiovascular Disorder Market by Country, 2018 - 2021, USD Million
TABLE 43 North America Cardiovascular Disorder Market by Country, 2022 - 2028, USD Million
TABLE 44 North America GIT & Renal Market by Country, 2018 - 2021, USD Million
TABLE 45 North America GIT & Renal Market by Country, 2022 - 2028, USD Million
TABLE 46 North America Antiinfection & Dermatology Market by Country, 2018 - 2021, USD Million
TABLE 47 North America Antiinfection & Dermatology Market by Country, 2022 - 2028, USD Million
TABLE 48 North America Respiratory Market by Country, 2018 - 2021, USD Million
TABLE 49 North America Respiratory Market by Country, 2022 - 2028, USD Million
TABLE 50 North America Central Nervous System Market by Country, 2018 - 2021, USD Million
TABLE 51 North America Central Nervous System Market by Country, 2022 - 2028, USD Million
TABLE 52 North America Cancer Market by Country, 2018 - 2021, USD Million
TABLE 53 North America Cancer Market by Country, 2022 - 2028, USD Million
TABLE 54 North America Pain Market by Country, 2018 - 2021, USD Million
TABLE 55 North America Pain Market by Country, 2022 - 2028, USD Million
TABLE 56 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 57 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 58 North America Peptide Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 59 North America Peptide Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 60 US Peptide Therapeutics Market, 2018 - 2021, USD Million
TABLE 61 US Peptide Therapeutics Market, 2022 - 2028, USD Million
TABLE 62 US Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 63 US Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 64 US Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
TABLE 65 US Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
TABLE 66 US Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
TABLE 67 US Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
TABLE 68 US Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
TABLE 69 US Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
TABLE 70 US Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
TABLE 71 US Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
TABLE 72 Canada Peptide Therapeutics Market, 2018 - 2021, USD Million
TABLE 73 Canada Peptide Therapeutics Market, 2022 - 2028, USD Million
TABLE 74 Canada Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 75 Canada Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 76 Canada Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
TABLE 77 Canada Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
TABLE 78 Canada Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
TABLE 79 Canada Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
TABLE 80 Canada Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
TABLE 81 Canada Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
TABLE 82 Canada Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
TABLE 83 Canada Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
TABLE 84 Mexico Peptide Therapeutics Market, 2018 - 2021, USD Million
TABLE 85 Mexico Peptide Therapeutics Market, 2022 - 2028, USD Million
TABLE 86 Mexico Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 87 Mexico Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 88 Mexico Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
TABLE 89 Mexico Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
TABLE 90 Mexico Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
TABLE 91 Mexico Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
TABLE 92 Mexico Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
TABLE 93 Mexico Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
TABLE 94 Mexico Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
TABLE 95 Mexico Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
TABLE 96 Rest of North America Peptide Therapeutics Market, 2018 - 2021, USD Million
TABLE 97 Rest of North America Peptide Therapeutics Market, 2022 - 2028, USD Million
TABLE 98 Rest of North America Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 99 Rest of North America Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 100 Rest of North America Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
TABLE 101 Rest of North America Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
TABLE 102 Rest of North America Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
TABLE 103 Rest of North America Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
TABLE 104 Rest of North America Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
TABLE 105 Rest of North America Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
TABLE 106 Rest of North America Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
TABLE 107 Rest of North America Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
TABLE 108 Key Information – Eli Lilly And Company
TABLE 109 KEY INFORMATION – ASTRAZENECA PLC
TABLE 110 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 111 Key Information – Novartis AG
TABLE 112 Key Information – Pfizer, Inc.
TABLE 113 Key Information – Sanofi S.A.
TABLE 114 Key Information – GlaxoSmithKline PLC
TABLE 115 Key Information – Takeda Pharmaceutical Company Limited
TABLE 116 Key Information – Lonza Group AG
TABLE 117 Key Information – Amgen, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Recent strategies and developments: Eli Lilly And Company
FIG 5 Recent strategies and developments: AstraZeneca PLC
FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 7 Recent strategies and developments: Novartis AG

Purchase Full Report of
North America Peptide Therapeutics Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL